Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TGFBR2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TGFBR2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TGFBR2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TGFBR2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TGFBR2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TGFBR2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TGFBR2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000170110 | Prostate | BPH | in utero embryonic development | 104/3107 | 367/18723 | 9.17e-09 | 3.10e-07 | 104 |
GO:001063216 | Prostate | BPH | regulation of epithelial cell migration | 87/3107 | 292/18723 | 1.18e-08 | 3.87e-07 | 87 |
GO:000640316 | Prostate | BPH | RNA localization | 65/3107 | 201/18723 | 2.76e-08 | 8.13e-07 | 65 |
GO:003367416 | Prostate | BPH | positive regulation of kinase activity | 122/3107 | 467/18723 | 8.59e-08 | 2.14e-06 | 122 |
GO:00715597 | Prostate | BPH | response to transforming growth factor beta | 76/3107 | 256/18723 | 1.14e-07 | 2.73e-06 | 76 |
GO:004586010 | Prostate | BPH | positive regulation of protein kinase activity | 104/3107 | 386/18723 | 1.52e-07 | 3.51e-06 | 104 |
GO:001063416 | Prostate | BPH | positive regulation of epithelial cell migration | 57/3107 | 176/18723 | 1.82e-07 | 4.04e-06 | 57 |
GO:00017638 | Prostate | BPH | morphogenesis of a branching structure | 61/3107 | 196/18723 | 3.33e-07 | 7.06e-06 | 61 |
GO:003166718 | Prostate | BPH | response to nutrient levels | 121/3107 | 474/18723 | 3.68e-07 | 7.70e-06 | 121 |
GO:002261210 | Prostate | BPH | gland morphogenesis | 42/3107 | 118/18723 | 4.36e-07 | 8.87e-06 | 42 |
GO:00715607 | Prostate | BPH | cellular response to transforming growth factor beta stimulus | 72/3107 | 250/18723 | 8.71e-07 | 1.61e-05 | 72 |
GO:190370616 | Prostate | BPH | regulation of hemopoiesis | 97/3107 | 367/18723 | 1.01e-06 | 1.83e-05 | 97 |
GO:00611385 | Prostate | BPH | morphogenesis of a branching epithelium | 56/3107 | 182/18723 | 1.48e-06 | 2.56e-05 | 56 |
GO:00605628 | Prostate | BPH | epithelial tube morphogenesis | 87/3107 | 325/18723 | 2.05e-06 | 3.39e-05 | 87 |
GO:00071797 | Prostate | BPH | transforming growth factor beta receptor signaling pathway | 57/3107 | 198/18723 | 1.17e-05 | 1.58e-04 | 57 |
GO:00459265 | Prostate | BPH | negative regulation of growth | 68/3107 | 249/18723 | 1.26e-05 | 1.69e-04 | 68 |
GO:00605377 | Prostate | BPH | muscle tissue development | 100/3107 | 403/18723 | 1.35e-05 | 1.76e-04 | 100 |
GO:002240716 | Prostate | BPH | regulation of cell-cell adhesion | 109/3107 | 448/18723 | 1.43e-05 | 1.85e-04 | 109 |
GO:00071788 | Prostate | BPH | transmembrane receptor protein serine/threonine kinase signaling pathway | 90/3107 | 355/18723 | 1.48e-05 | 1.90e-04 | 90 |
GO:00018376 | Prostate | BPH | epithelial to mesenchymal transition | 47/3107 | 157/18723 | 2.21e-05 | 2.67e-04 | 47 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TGFBR2 | SNV | Missense_Mutation | | c.1528G>A | p.Glu510Lys | p.E510K | P37173 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
TGFBR2 | SNV | Missense_Mutation | | c.382G>A | p.Asp128Asn | p.D128N | P37173 | protein_coding | tolerated(0.83) | benign(0.061) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
TGFBR2 | SNV | Missense_Mutation | novel | c.673A>G | p.Thr225Ala | p.T225A | P37173 | protein_coding | tolerated(0.89) | benign(0) | TCGA-LL-A50Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
TGFBR2 | SNV | Missense_Mutation | | c.1559N>A | p.Arg520Gln | p.R520Q | P37173 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-LL-A9Q3-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Immunotherapy | herceptin | CR |
TGFBR2 | insertion | Nonsense_Mutation | novel | c.939_940insTTGCAGTGAGCAGAGATCGTGCCATTGCACTGCTGCCTGGGTA | p.Thr314LeufsTer3 | p.T314Lfs*3 | P37173 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TGFBR2 | SNV | Missense_Mutation | novel | c.116A>C | p.Lys39Thr | p.K39T | P37173 | protein_coding | tolerated_low_confidence(0.15) | benign(0.026) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | rs886039551 | c.1411N>A | p.Asp471Asn | p.D471N | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | | c.1664N>T | p.Thr555Ile | p.T555I | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TGFBR2 | SNV | Missense_Mutation | | c.1393G>A | p.Glu465Lys | p.E465K | P37173 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TGFBR2 | SNV | Missense_Mutation | rs104893809 | c.1684C>T | p.Arg562Cys | p.R562C | P37173 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | agonist | 178101755 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | TGF-BR2 mab | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | TG-C | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565755 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565835 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | agonist | 348353672 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | irinotecan | IRINOTECAN | 27160286 |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565874 | | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 223366128 | GALUNISERTIB | |
7048 | TGFBR2 | KINASE, SERINE THREONINE KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 249565800 | | |